- Home
- KOD vs DRUG Comparison
KOD vs DRUG Comparison
Compare KOD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- DRUG
- Stock Information
- Founded
- KOD 2009
- DRUG 2019
- Country
- KOD United States
- DRUG United States
- Employees
- KOD N/A
- DRUG N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- DRUG Pharmaceuticals and Biotechnology
- Sector
- KOD Health Care
- DRUG Health Care
- Exchange
- KOD Nasdaq
- DRUG Nasdaq
- Market Cap
- KOD 186.3M
- DRUG 210.7M
- IPO Year
- KOD 2018
- DRUG N/A
- Fundamental
- Price
- KOD $5.33
- DRUG $42.95
- Analyst Decision
- KOD Hold
- DRUG
- Analyst Count
- KOD 5
- DRUG 0
- Target Price
- KOD $3.25
- DRUG N/A
- AVG Volume (30 Days)
- KOD 395.9K
- DRUG 2.4M
- Earning Date
- KOD 11-26-2024
- DRUG 11-18-2024
- Dividend Yield
- KOD N/A
- DRUG N/A
- EPS Growth
- KOD N/A
- DRUG N/A
- EPS
- KOD N/A
- DRUG N/A
- Revenue
- KOD N/A
- DRUG N/A
- Revenue This Year
- KOD N/A
- DRUG N/A
- Revenue Next Year
- KOD N/A
- DRUG N/A
- P/E Ratio
- KOD N/A
- DRUG N/A
- Revenue Growth
- KOD N/A
- DRUG N/A
- 52 Week Low
- KOD $1.90
- DRUG $0.93
- 52 Week High
- KOD $7.77
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- KOD 76.60
- DRUG 56.70
- Support Level
- KOD $3.73
- DRUG $36.02
- Resistance Level
- KOD $5.58
- DRUG $50.25
- Average True Range (ATR)
- KOD 0.28
- DRUG 6.35
- MACD
- KOD 0.11
- DRUG -2.47
- Stochastic Oscillator
- KOD 88.02
- DRUG 31.53
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.